Article

Mining the complement system for lupus biomarkers

Clinical and Applied Immunology Reviews 01/2005; 5(3):185-206. DOI: 10.1016/j.cair.2005.01.004

ABSTRACT Systemic lupus erythematosus (SLE) is a chronic multiorgan autoimmune disease. Activation of the complement system plays a fundamental role in the pathogenesis of SLE. For the past several decades, laboratory monitoring of SLE has focused primarily on measurement of serum C3, C4, and their activation products. However, the utility of these measures as biomarkers for diagnosis and assessment of disease activity of SLE is still debated. Over the same time span, knowledge of the complement system has advanced remarkably, with more than 30 proteins identified. In view of the urgent need for identifying reliable lupus biomarkers, it is appropriate to revisit the issue of whether the complement system is a potential source of biomarkers for SLE. This article will review historical aspects of complement measurement in SLE, and summarize recent advances that may lead to a newly rejuvenated “gold rush” to mine the complement system for biomarkers of SLE. Specifically, development and utility of a novel assay that measures cell-bound complement activation products as lupus biomarkers will be discussed.

0 Bookmarks
 · 
53 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aim of the studyRadix Bupleuri, is one of the most frequently prescribed crude herbs in the prescriptions of traditional Chinese medicine for the treatment of inflammatory diseases and auto-immune diseases. This study was to determine whether the crude polysaccharides (BPs) isolated from the roots of Bupleurum smithii var. parvifolium, had beneficial effects on autoimmune disease.Materials and methodsBALB/c mice were immunized with CJ-S131 in Freund's complete adjuvant on day 0, and then boosted on day 14. BPs 15 or 30 mg kg−1 day−1, or prednisone 5 mg kg−1 day−1 was given to BALB/c mice intragastrically from day 0 to day 34.ResultsTreatment with BPs 15 or 30 mg kg−1 day−1 for 35 days protected kidney from glomerular injury with reduced immunoglobulin deposition and lowered proteinuria. The increased production of serum autoantibodies and total immunoglobulin G (IgG) was also inhibited. BPs 30 mg kg−1 day−1 improved weight loss and spleen swelling when compared with vehicle-treated group.ConclusionsThese findings suggested that Bupleurum polysaccharides had a beneficial effect on systemic lupus erythematosus-like syndroma induced by CJ-S131 in BALB/c mice.
    Journal of ethnopharmacology 06/2009; · 2.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The stem bark of Eucommia ulmoides Oliv. is commonly used for the treatment of hypertension, rheumatoid arthritis, lumbago, and ischialgia in traditional Chinese medicine. This study was to determine whether the crude polysaccharides (EUPs) isolated from the stem bark of E. ulmoides had beneficial effects on lupus-like syndrome in mice. BALB/c mice were immunized with CJ-S(131) in Freund's complete adjuvant on day 0, and then boosted on day 14. EUPs 15 or 30 mg kg(-1)·day(-1), or prednisone 5 mg kg(-1)·day(-1) was given to BALB/c mice intragastrically from day 0 to 34. Treatment with EUPs 15 or 30 mg kg(-1)·day(-1) for 35 days protected kidney from glomerular injury with reduced immunoglobulin deposition and lowered proteinuria. The increased production of serum autoantibodies and total immunoglobulin G (IgG) was also inhibited. These findings suggested that Eucommia polysaccharides had a beneficial effect on systemic lupus erythematosus-like syndrome induced by CJ-S(131) in BALB/c mice.
    Inflammation 10/2011; 34(5):402-11. · 2.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to investigate the serum RANTES (regulated on activation, normal T-cell expressed and secreted) level in patients with systemic lupus erythematosus (SLE), and the associations with disease activity and clinical laboratory indexes. Twenty-seven SLE patients and 27 normal controls were enrolled in this study. Serum RANTES was measured by enzyme-linked immunosorbent assay (ELISA). The clinical and laboratory parameters of the patients were also recorded. Results showed that serum RANTES level was significantly elevated in SLE patients when compared with normal controls. Serum RANTES level was correlated with C3, ANA, anti-dsDNA antibodies, anti-Sm antibodies, and anti-SSB antibodies. Nevertheless, no association of serum RANTES level with SLEDAI was found. Taken together, serum RANTES level was significantly higher in SLE patients, suggesting that RANTES might be involved in the pathogenesis of SLE.
    Rheumatology International 05/2011; 32(5):1231-3. · 2.21 Impact Factor